• Nenhum resultado encontrado

Long non-coding RNAs as potential therapeutic targets in human breast cancer

N/A
N/A
Protected

Academic year: 2021

Share "Long non-coding RNAs as potential therapeutic targets in human breast cancer"

Copied!
44
0
0

Texto

Loading

Imagem

Table 1.1: Therapeutic agents and corresponding mechanisms of action, specific to each breast cancer subtype
Figure 1.1: NORAD activation or inactivation and subsequent events. Upon DNA damage and in a p53-dependent manner,  NORAD is activated and sequesters Pumilio proteins, limiting the repression of target mRNAs involved in mitosis, DNA repair
Table 3.2: Gene-specific primer pairs and sequences used in RT-qPCR. The genes of interest are NORAD and p53, while  the housekeeping genes are β-actin and 18S
Table  3.3:  Protein-specific  antibodies  used  in  western  blot.  The  proteins  of  interest  are  p53  and  γH2AX,  while  the  housekeeping protein is β-actin
+7

Referências

Documentos relacionados

Lupeportlandol acetate was inactive in cytotoxicity assays in vitro against three human tumor cell lines: MCF-7 (breast cancer), NCI-H460 (non-small cell lung cancer) and SF-268

Antitumor activity assays of the new complexes using the invasive MDA-MB-231 and non-invasive MCF-7 human breast tumor cell lines indicated a good degree of cytotoxicity for

Lectin binding properties of human breast cancer cell lines and human milk with particular reference for helix

We compared the proliferation of the human breast cancer cell line MDA-MB-231 and of the non-cancer human mammary epithelial cell line MCF-10A in different experimental

The cytotoxicity assays were performed using the tumor cell lineages UACC-62 (human melanoma), MCF-7 (human breast cancer) and TK-10 (human renal cancer).. The cell lineages were

The organic crude extracts, phases and compounds assays were performed using the tumor cell lines UACC-62 (human melanoma cancer), MCF-7 (human breast cancer) and

A panel of nine human cancer cell lines, i.e., MCF-7 (breast), NCI/ADR-RES (ovarian cancer with a phenotype of multiple-drug resistance), UACC-62 (melanoma), NCI- H460 (non-small

MCF-7 (Human breast cancer cell line), SGC7901 (human gastric carcinoma cell line), LS-174T (human colon adenocarcinoma cell line) and A549 (human lung adenocarcinoma cell)